BioWorld

Nov. 3, 2003

CV Therapeutics Stock Drops On Ranexa Approvable Letter

CV Therapeutics Inc. received a mixed bag of news related to Ranexa, its lead compound for chronic angina, and investors took the news badly as the company's stock slipped 21.7 percent Friday. (BioWorld Today) Read More

Fast Action Urged To Rescue Reef Cone Snails From Global Warming, To Garner Rich Trove Of Medicines

With Venter On Board, Ionian Has Biothreat Detection Focus

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 30, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 30, 2026.

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...